Repligen (RGEN) Tops Q2 EPS by 6c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.31, $0.06 better than the analyst estimate of $0.25. Revenue for the quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)